The Board of Directors of Affymax, Inc. (OTCPK:AFFY) is reviewing its strategic options as a result of the termination of the collaboration with Takeda Pharmaceutical Company Limited (TSE:4502). Affymax and Takeda would terminate their Omontys product partnership in September. The firms would also withdraw their new drug application with the U.S. Food and Drug Administration.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0008 USD | +6.67% | 0.00% | +33.33% |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 55.87K | |
+31.37% | 50.85B | |
+1.21% | 42.82B | |
+48.83% | 42.03B | |
-4.22% | 29.55B | |
+10.98% | 26.11B | |
-22.30% | 19.13B | |
+7.59% | 13.05B | |
+26.80% | 12.16B | |
+22.92% | 12.08B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax To Review Strategic Options